Marshall Dennis E 4

What Happened
Dennis E. Marshall, a director of BioLargo, Inc. (BLGO), was granted two derivative awards (stock options) on March 31, 2026 covering 138,889 and 115,741 shares—totaling 254,630 underlying shares. The grants were issued as compensation and as replacements for previously issued options; the filing does not report an exercise price or immediate sale, so no cash value is provided. This was an award/grant of options (not a purchase or sale).

Key Details

• Transaction date: 2026-03-31; Form 4 filed 2026-04-01 (timely filing within required window).
• Reported amounts: 138,889 shares (award) and 115,741 shares (award); aggregate 254,630 underlying shares.
• Exercise price / total dollar value: Not reported in the provided filing excerpt (N/A).
• Shares owned after transaction: Not specified in the provided data.
• Notable footnotes:
  • F1: One option grant replaces an option to purchase 68,182 shares that had expired unexercised (original option issued as compensation of $22,500).
  • F2: Confirms expiration of options to purchase 68,182 shares on March 31, 2026.
  • F3: One option was issued as payment for $18,750 in board fees under the Issuer’s 2024 Equity Incentive Plan; the option share count equals fees divided by exercise price.
• Transaction type code: A = Award/Grant (derivative options).

Context
These filings report option grants used as director compensation and to replace expired options. Option awards are common as equity compensation and do not by themselves indicate immediate buying or selling of stock by the insider. Because the exercise price and any vesting or expiration terms are not disclosed here, retail investors cannot infer the immediate economic value or timing for potential exercise or sale.